Navigation Links
Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis

- The first approval for an antibody generated from Medarex's UltiMAb(R) technology platform -

PRINCETON, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it will receive a milestone payment from its licensing partner, Centocor Inc., in connection with the recently announced marketing approval from Health Canada's Biologics and Genetic Therapies Directorate, to market STELARA (ustekinumab, previously known as CNTO 1275) for the treatment of moderate to severe plaque psoriasis, as an infrequently administered subcutaneous injection.

STELARA, generated using Medarex's UltiMAb(R) technology, is a human monoclonal antibody with a novel mechanism of action that targets certain cytokines, naturally occurring proteins that are important in the body's regulation of immune responses and that are believed to play a role in immune-mediated inflammatory disorders, including psoriasis. Regulatory applications for marketing authorization for STELARA have been filed in the United States and Europe. Under the agreement with Centocor Inc., Medarex will receive future sales-based royalty payments from the commercial sale of STELARA.

"STELARA marks the first approval by a major regulatory authority of an antibody generated from our UltiMAb(R) technology platform and represents a great achievement for Medarex," said Howard H. Pien, Chairman and CEO of Medarex. "This approval marks a highly visible milestone for our UltiMAb(R) technology platform and the important role of Medarex in enabling human monoclonal antibodies in expanding treatment options for patients with underserved medical needs. In addition, we look forward to the royalty stream generated by future sales of this product which will assist with continued investment in our own research and development programs."

Centocor first licensed Medarex's UltiMAb(R) technology for the generation of human antibodies in 1997. The agreement was expanded in 2000 to allow Centocor greater access to Medarex's technology. In 2007, the relationship was extended to provide Centocor with continued access to Medarex's UltiMAb(R) technology. Other antibodies generated from Medarex's UltiMAb(R) technology in development by Centocor or its partners include golimumab (also known as CNTO 148), currently under review for marketing approval as a once-monthly subcutaneous anti-TNF-alpha human antibody in the U.S. and in Europe for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase 2 for the treatment of ulcerative colitis; and CNTO 95, an anti-integrin human antibody in Phase 2 development for the treatment of cancer.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believe"; "future"; "potential" or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with the development and commercialization of STELARA, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid or that STELARA will be commercially successful. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. STELARA(TM) is a trademark of Centocor, Inc. All rights are reserved.

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
2. Medarex Announces 2008 First Quarter Financial Results
3. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
4. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
7. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
8. Medarex to Present at the JPMorgan Small/Mid Cap Conference
9. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
10. Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release
11. University of Minnesota receives $40 million for type 1 diabetes research
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... The recently published 32nd Annual Report ... reveals that in 2014, someone called a poison center about every 11 seconds. ... were human exposure cases. , The American Association of Poison Control Centers (AAPCC) ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... as their exclusive channel partner for the Nutraceutical Specialties products into oral solid ... US, effective immediately. , “We are pleased to announce our expanded distribution ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, ... Matrix Surgical Mesh technology for soft tissue repair in the US via Insightra’s ... long-term resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Booth #4303 – The Imaging Components business of ... broader array of products in a new booth (#4303) at ... North America in Chicago ... X-ray components "At the Heart of Imaging." Products will include ... Varian,s Claymount brand, and computer-aided diagnostic software from MeVis as ...
(Date:11/30/2015)... Wash. , Nov. 30, 2015  Precision ... Post-Processing services, is pleased to announce a dramatic ... medical imaging services. Building on its ISO-9001:2008 certification ... and implemented comprehensive Core Lab protocols and procedures. ... variety of research activities.  Their Core Lab services ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology: